These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37036268)

  • 1. Impact of coronary artery disease on clinical outcomes after TAVR: Insights from the BRAVO-3 randomized trial.
    Feldman D; Cao D; Sartori S; Zhang Z; Hengstenberg C; Tron C; Anthopoulos P; Widder JD; Meneveau N; Stella PR; Ferrari M; Jeger R; Violini R; Dumonteil N; Chen S; Yan R; Nicolas J; Razuk V; Spirito A; Vogel B; Mehran R; Dangas G
    Catheter Cardiovasc Interv; 2023 May; 101(6):1134-1143. PubMed ID: 37036268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex-based differences in outcomes with bivalirudin or unfractionated heparin for transcatheter aortic valve replacement: Results from the BRAVO-3 randomized trial.
    Asgar A; Chandrasekhar J; Mikhail G; Webb J; Lefèvre T; Tamburino C; Hildick-Smith D; Hambrecht R; Van Belle E; Widder J; Dumonteil N; Hink U; Jeger R; Linke A; Deliargyris E; Gao P; Mehran R; Hengstenberg C; Anthopoulos P; Dangas G;
    Catheter Cardiovasc Interv; 2017 Jan; 89(1):144-153. PubMed ID: 27152677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO-3 randomized trial.
    Zilberszac R; Chandiramani R; Hengstenberg C; Sartori S; Cao D; Chandrasekhar J; Schafer U; Tchetche D; Violini R; Jeger R; Van Belle E; Boekstegers P; Hambrecht R; Tron C; Dumenteil N; Linke A; Ten Berg JM; Deliargyris EN; Anthopoulos P; Mehran R; Dangas G
    Catheter Cardiovasc Interv; 2020 Sep; 96(3):E377-E386. PubMed ID: 31808295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial.
    Dangas GD; Lefèvre T; Kupatt C; Tchetche D; Schäfer U; Dumonteil N; Webb JG; Colombo A; Windecker S; Ten Berg JM; Hildick-Smith D; Mehran R; Boekstegers P; Linke A; Tron C; Van Belle E; Asgar AW; Fach A; Jeger R; Sardella G; Hink HU; Husser O; Grube E; Deliargyris EN; Lechthaler I; Bernstein D; Wijngaard P; Anthopoulos P; Hengstenberg C;
    J Am Coll Cardiol; 2015 Dec; 66(25):2860-2868. PubMed ID: 26477635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of anemia on short-term outcomes after TAVR: A subgroup analysis from the BRAVO-3 randomized trial.
    Razuk V; Camaj A; Cao D; Nicolas J; Hengstenberg C; Sartori S; Zhang Z; Power D; Beerkens F; Chiarito M; Meneveau N; Tron C; Dumonteil N; Widder JD; Ferrari M; Violini R; Stella PR; Jeger R; Anthopoulos P; Mehran R; Dangas GD
    Catheter Cardiovasc Interv; 2021 Nov; 98(6):E870-E880. PubMed ID: 33909348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence, predictors, and outcomes associated with acute kidney injury in patients undergoing transcatheter aortic valve replacement: from the BRAVO-3 randomized trial.
    Chandrasekhar J; Sartori S; Mehran R; Aquino M; Vogel B; Asgar AW; Webb JG; Tchetche D; Dumonteil N; Colombo A; Windecker S; Claessen BE; Ten Berg JM; Hildick-Smith D; Wijngaard P; Lefèvre T; Deliargyris EN; Hengstenberg C; Anthopoulos P; Dangas GD
    Clin Res Cardiol; 2021 May; 110(5):649-657. PubMed ID: 33839885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial.
    Linke A; Chandrasekhar J; Sartori S; Lefevre T; van Belle E; Schaefer U; Tchetche D; Sardella G; Webb J; Colombo A; Windecker S; Vogel B; Farhan S; Sorrentino S; Sharma M; Snyder C; Asgar A; Dumonteil N; Tamburino C; Hink U; Violini R; Stella P; Bernstein D; Deliargyris E; Hengstenberg C; Baber U; Mehran R; Anthopoulos P; Dangas G;
    Catheter Cardiovasc Interv; 2017 Nov; 90(6):1016-1026. PubMed ID: 28498562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVO-3 trial.
    Camaj A; Claessen BE; Mehran R; Yudi MB; Power D; Baber U; Hengstenberg C; Lefevre T; Van Belle E; Giustino G; Guedeney P; Sorrentino S; Kupatt C; Webb JG; Hildick-Smith D; Hink HU; Deliargyris EN; Anthopoulos P; Sharma SK; Kini A; Sartori S; Chandrasekhar J; Dangas GD
    Catheter Cardiovasc Interv; 2020 Dec; 96(7):E688-E694. PubMed ID: 31943717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study.
    Chang CC; Chichareon P; Modolo R; Takahashi K; Kogame N; Tomaniak M; Gao C; Royaards KJ; Cequier A; Oldroyd K; Steg PG; Hamm C; Jüni P; Valgimigli M; Windecker S; Onuma Y; Stables RH; Jan van Geuns R; Serruys PW
    Eur Heart J Cardiovasc Pharmacother; 2020 Jan; 6(1):22-30. PubMed ID: 31841136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes of Bivalirudin Versus Heparin in Elderly Patients Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Meng S; Xu J; Guo L; Huang R
    Cardiovasc Drugs Ther; 2020 Feb; 34(1):101-111. PubMed ID: 32100149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of unfractionated heparin or bivalirudin on patients with stable coronary artery disease undergoing percutaneous coronary intervention.
    Lima FV; Gruberg L; Aslam U; Ramgadoo M; Clase K; Trevisan A; Jeremias A
    J Interv Cardiol; 2018 Apr; 31(2):177-184. PubMed ID: 29205487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of bivalirudin versus heparin in transradial coronary interventions.
    Kheiri B; Rao SV; Osman M; Simpson TF; Barbarawi M; Zayed Y; Dhillon HN; Alkhouli M; Golwala H; Zahr F; Bhatt DL; Stone GW; Cigarroa JE
    Catheter Cardiovasc Interv; 2020 Nov; 96(6):1240-1248. PubMed ID: 32091668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of pre-existing or new-onset atrial fibrillation on 30-day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial.
    Hengstenberg C; Chandrasekhar J; Sartori S; Lefevre T; Mikhail G; Meneveau N; Tron C; Jeger R; Kupatt C; Vogel B; Farhan S; Sorrentino S; Sharma M; Snyder C; Husser O; Boekstegers P; Hambrecht R; Widder J; Hildick-Smith D; De Carlo M; Wijngaard P; Deliargyris E; Bernstein D; Baber U; Mehran R; Anthopoulos P; Dangas G;
    Catheter Cardiovasc Interv; 2017 Nov; 90(6):1027-1037. PubMed ID: 28493641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).
    Patti G; Pasceri V; D'Antonio L; D'Ambrosio A; Macrì M; Dicuonzo G; Colonna G; Montinaro A; Di Sciascio G
    Am J Cardiol; 2012 Aug; 110(4):478-84. PubMed ID: 22583760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebral Embolism During Transcatheter Aortic Valve Replacement: The BRAVO-3 MRI Study.
    Van Belle E; Hengstenberg C; Lefevre T; Kupatt C; Debry N; Husser O; Pontana F; Kuchcinski G; Deliargyris EN; Mehran R; Bernstein D; Anthopoulos P; Dangas GD;
    J Am Coll Cardiol; 2016 Aug; 68(6):589-599. PubMed ID: 27208464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Bivalirudin versus Unfractionated Heparin Monotherapy in Patients with CAD and DM Undergoing PCI: A Retrospective Observational Study.
    Li J; Chen S; Ma S; Yang M; Qi Z; Na K; Qiu M; Li Y; Han Y
    Cardiovasc Ther; 2022; 2022():5352087. PubMed ID: 36530956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of bivalirudin during percutaneous coronary intervention in high-bleeding-risk elderly patients with chronic total occlusion: A prospective randomized controlled trial.
    Wang Y; Zhao HW; Wang CF; Fan CY; Zhang XJ; Zhu Y; Luo DF; Yu GN; Hou AJ; Luan B
    Catheter Cardiovasc Interv; 2019 Feb; 93(S1):825-831. PubMed ID: 30724035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel approaches for preventing or limiting events (Naples) III trial: randomized comparison of bivalirudin versus unfractionated heparin in patients at increased risk of bleeding undergoing transfemoral elective coronary stenting.
    Briguori C; Visconti G; Focaccio A; Donahue M; Golia B; Selvetella L; Ricciardelli B
    JACC Cardiovasc Interv; 2015 Mar; 8(3):414-423. PubMed ID: 25703878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of bivalirudin in elderly patients with coronary artery disease undergoing percutaneous coronary intervention: A real-world study.
    Li J; Liu X; Ma S; Na K; Qi Z; Xu Y; Qiu M; Han Y; Li Y
    Catheter Cardiovasc Interv; 2022 May; 99 Suppl 1():1448-1455. PubMed ID: 35077603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The comparative safety and effectiveness of bivalirudin versus heparin monotherapy in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan cardiovascular consortium.
    Sukul D; Seth M; Schreiber T; Khandelwal A; Cannon LA; LaLonde TA; Gurm HS
    Catheter Cardiovasc Interv; 2017 Nov; 90(5):724-732. PubMed ID: 28303632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.